University of Thessaly (UTH)
Παράγοντες κινδύνου αθηροσκλήρωσης σε ασθενείς με μεγαλακρία χαμηλής δραστηριότητας
Abstract
dc:descriptionINTRODUCTION. Acromegaly is characterized by metabolic alterations (hypertension, disturbances in glucose homeostasis, dyslipidemia etc), and increased morbidity/mortality, mainly due to increased frequency of cardiovascular disease. The biochemical cure of acromegaly is associated with favorable changes in cardiovascular risk factors, as well as amelioration of the increased morbidity/mortality. Nevertheless, despite the progress in the management of acromegaly, in many cases the current strict criteria for cure of acromegaly are not fulfilled (partial remission: low-activity disease). Until today, it has not been clarified if the partial cure of the disease is accompanied by favorable changes in cardiovascular risk factors. AIMS. Comparison of atherosclerosis risk factors between healthy controls and patients with a) active acromegaly, b) low-activity acromegaly, c) GH deficiency. PATIENTS-METHODS. Initially, were studied 41 patients with active acromegaly, 15 healthy controls and 24 patients with GH deficiency. Following, 18 out of the total 41 patients with acromegaly were studied after treatment with somatostatin analogues for six months (low-activity acromegaly group). The following parameters were estimated: body weight, BMI, WHR, blood pressure, total, HDL-, LDL-cholesterol, triglycerides, Lp(a), ApoA-I, ApoB, glucose, insulin, HbA1c, HOMA, OGTTISI, fibrinogen, t-PA, PAI-1, hs-CRP and thrombomodulin. RESULTS. In all patients with abnormal GH production (either excess or deficiency), dyslipidemia, high fibrinogen and increased insulin resistance were recorded. Patients with acromegaly also had higher insulin, Lp(a), t-PA and HbA1c levels and lower ApoA-I. ΡΑΙ-1 and thrombomodulin were not different. Patients with GH deficiency had the highest total and LDL-cholesterol. Finally, hs-CRP was higher in patients with GH deficiency and lower in patients with acromegaly. All patients with acromegaly responded to somatostatin analogues, as proved by the decrease in serum GH and IGF-I levels. Nevertheless, according to the strict cure criteria, the 18 studied patients still had low-activity disease. After treatment there was significant decrease in: blood pressure, glucose, insulin, HbA1c, total and LDL-cholesterol, triglycerides, Lp(a), fibrinogen, PAI-1 and t-PA levels. On the other hand, there was significant increase in: ApoA-I, HDL-cholesterol, OGTTISI and hs-CRP levels, whereas ApoB and thrombomodulin levels did not change. Patients with low-activity acromegaly patients did not differ from healthy controls in most parameters studied, except for still remaining more insulin resistant and exhibiting higher Lp(a), fibrinogen and t-PA and lower HDL-cholesterol. CONCLUSIONS. 1. Patients with abnormal GH production (either excess or deficiency) have had, in the same extend, a cluster of cardiovascular risk factors (dyslipidemia, coagulation dysfunction, insulin resistance), indicating the role of GH in metabolic homeostasis. 2. There was observed a negative correlation between hs-CRP and GH. However, hs-CRP does not seem to be a cardiovascular risk factor in acromegaly. 3. For the studied parameters, where a significant relationship was observed with GH and/or IGF-I levels, the correlation was not linear but U-shaped, with GH excess and deficiency occupying the ends. 4. The partial cure of the disease (low-activity acromegaly), after treatment with somatostatin improved significantly many cardiovascular risk factors, such as hyperinsulinemia, insulin resistance, disturbances in glucose homeostasis, hypertension, lipidemic profile and several coagulation factors.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Delaroudis, Sideris
- Δελαρούδης, Σιδέρης
Subjects
dc:subject × 23- Μεγαλακρία
- Ακρομεγαλία
- Αθηροσκλήρωση
- Αθηρωμάτωση
- Ανάλογα σωματοστατίνης
- Παράγοντες καρδιαγγειακού κινδύνου
- Ινσουλίνη, Αντίσταση στην
- Ινσουλινοαντίσταση
- Λιπίδια
- Παράγοντες μηχανισμού πήξης
- Δείκτες φλεγμονής
- Acromegaly
- Atherosclerosis
- Somatostatin analogs
- Cardiovascular risk factors
- Insulin resistance
- Lipids
- Coagulation indices
- Inflammation indices
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18163